Skyhawk Therapeutics
CompanyUnited States
Skyhawk Therapeutics develops one asset, in phase 2 (SKY-0515 in Huntington's disease). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $48M
- 1
- Trial
- 0
- Signals
Pipeline
1Modulates RNA splicing to reduce huntingtin and PMS1 expression.
Phase 2, Small molecule, Huntington's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants2
- Signals1
- Similar companies6